Schizophrenia Drugs Market will Register Significant Gain, B

The increasing prevalence of chronic and mental disorder is a key factor expected to enable growth in the global schizophrenia drugs market, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.” The global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is projected to reach USD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.







To gain more insights into the market, click here: www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531

Key Segmentation of Schizophrenia Drugs Market:



Schizophrenia Drugs Market Segments by Therapeutic Class



Second Generation

Third Generation

Others

Schizophrenia Drugs Market Segments by Treatment



Oral

Injectable

Schizophrenia Drugs Market Segments by Distribution Channel



Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

By Geography



North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)